Tag Archives: drug development

“Alz” Well That Ends Well: The Beta-Amyloid Debate in Alzheimer’s Research


Researchers and clinicians alike believe there is substantial evidence to support the hypothesis that Alzheimer’s disease (AD) may be caused by deposition of amyloid beta-peptide (Abeta) in plaques in brain tissue. But drugs targeted towards the beta-amyloid have met with significant setbacks challenging whether the target is, in fact, real. With several late stage drugs targeting beta-amyloid poised for market entry, a panel of opinion leaders in the treatment of Alzheimer’s and scientific industry specialists Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

The Real Reason Why Salk Refused to Patent the Polio Vaccine


Editor’s Note: Despite the progress in polio and other diseases made possible by vaccines, today we are witnessing a resurgence of vaccine-preventable illnesses as nervous parents skip their children’s shots. Watch the PBS documentary Vaccines—Calling the Shots to find learn more.  BIO is also a leading voice on the patent-ability of biotech inventions and other IP matters. To get the most recent updates on IP in the biotech world, please sign up for BIO’s free bi-monthly IP Newsletter. Read More >

Patently BIOtech  |  24 Comments  |  Email This Post
Tags: , , , , , , ,

IBM’s Watson: From Jeopardy! to Drug Research

IBM's Watson Computer System Plays Jeopardy! in a Practice Round

Bits of technology from I.B.M.’s Watson are beginning to be used in actual products available to corporate clients. The cloud-based Strategic Intellectual Property Insight Platform “uses data mining, natural-language processing and analytics to pore through millions of patent filings and biomedical journals to look for chemical compounds used in drug discovery.” As a byproduct of this project, I.B.M. is contributing their research to the searchable NIH chemical database, which will ease access to information previously Read More >

Health  |  1 Comment  |  Email This Post
Tags: , ,

Where’s the Deal?


With only two weeks to go in 2011 it is looking like a five year low for deals. The chart below shows therapeutic deals dropping every year since 2007. We use the Windhover/Elsevier Strategic Transaction Database as our starting point for deal analytics. We analyze each deal to determine if the deal is for a drug asset, removing generic/OTC deals, manufacturing/service deals, device/diagnostics/tools deals, and tech transfer deals. What remains are deals for biotech company Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Diabetes and Biotechnology: A Shared History…A Great Future


By David Welch, President/Senior Producer at M2 MultiMedia One of my closest childhood friends suffered from Type I Diabetes. Like millions of other children and adults his daily life was frequently interrupted with finger pokes, sugar level tests, and insulin shots. Having grown up with a friend afflicted with Diabetes and knowing dozens of others, throughout my life, with the same disease, it was very rewarding to produce a film on the topic. Although Bobby and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,